

## Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 2, 2021 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer, today announced that Curis management will participate in virtual fireside chats and panels at the following upcoming conferences in November and December:

30<sup>th</sup> Annual Credit Suisse Healthcare Conference on Monday, November 8, 2021 at 1:00 p.m. ET

Jim Dentzer, President and CEO, will participate in the virtual fireside chat.

12<sup>th</sup> Annual Jefferies Global Healthcare Conference, starting on Thursday, November 18, 2021 at 3:00 a.m. ET (8:00 a.m. GMT).

Jim Dentzer, President and CEO, will participate in the virtual fireside chat that will be available for on-demand viewing during the conference.

B. Riley Fall Best Ideas in Oncology Panel Series on Wednesday, December 1, 2021 at 11:00 a.m. ET

Robert Martell, Head of Research and Development, will participate on the oncology panel series titled "Emerging Targeted Therapies in Acute Myeloid Leukemia"

Live webcasts of the Credit Suisse and B. Riley presentations will be available under "Events & Presentations" in the Investors section of the Company's website at [www.curis.com](http://www.curis.com). Archived replays for all the events will be available on the Curis website for approximately 90 days following the event.

### About Curis, Inc.

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1/2 trial in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1/2 trial in patients with acute myeloid leukemia and myelodysplastic syndromes, for which it has received Orphan Drug Designation from the U.S. Food and Drug Administration. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1 trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at [www.curis.com](http://www.curis.com).

SOURCE Curis, Inc.

For further information: Elif McDonald, VP, Investor Relations and Corporate Communications, Curis, Inc., 617-503-6583, [emcdonald@curis.com](mailto:emcdonald@curis.com)

---

<https://investors.curis.com/2021-11-02-Curis-to-Present-at-Upcoming-Investor-Conferences>